{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:02:40Z","timestamp":1791406960543,"version":"4.3.3"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.bbcan.2004.05.002","type":"journal-article","created":{"date-parts":[[2004,6,18]],"date-time":"2004-06-18T10:55:01Z","timestamp":1087556101000},"page":"49-57","source":"Crossref","is-referenced-by-count":59,"title":["RANKL\/RANK\/OPG: new therapeutic targets in bone tumours and associated osteolysis"],"prefix":"10.1016","volume":"1704","author":[{"given":"Y.","family":"Wittrant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Th\u00e9oleyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chipoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Padrines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"R\u00e9dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2004.05.002_BIB1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i3-4.60","article-title":"Mechanisms of tumor metastasis to bone","volume":"10","author":"Weber","year":"2000","journal-title":"Crit. Rev. Eukaryot. Gene Expr"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/276726a0","article-title":"Direct resorption of bone by human breast cancer cells in vitro","volume":"276","author":"Eilon","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/er.19.1.18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr. Rev"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB8","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S1359-6446(01)02037-2","article-title":"Osteoprotegerin: a new therapeutic agent for the treatment of bone disease","volume":"6","author":"Grimaud","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jso.10067","article-title":"Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors","volume":"79","author":"Good","year":"2002","journal-title":"J. Surg. Oncol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB10","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0002-9440(10)63560-2","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL)\/osteoprotegerin (OPG) ratio is increased in severe osteolysis","volume":"163","author":"Grimaud","year":"2003","journal-title":"Am. J. Pathol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB11","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2002.03417.x","article-title":"RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma","volume":"117","author":"Roux","year":"2002","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB13","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB14","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1200\/JCO.2002.20.1.353","article-title":"Human bone marrow myeloma cells express RANKL","volume":"20","author":"Sezer","year":"2002","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB16","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB17","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappaB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB18","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","article-title":"Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease","volume":"98","author":"Seidel","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB19","first-page":"2306","article-title":"Serum osteoprotegerin levels in healthy controls and cancer patients","volume":"8","author":"Lipton","year":"2002","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB20","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalised and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB21","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V99.2.634","article-title":"Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kB ligand on adult T-cell leukemia cells","volume":"99","author":"Nosaka","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/jcp.55.11.877","article-title":"Tumour cells produce receptor activator of NF-kB ligand (RANKL) in skeletal metastases","volume":"55","author":"Huang","year":"2002","journal-title":"J. Clin. Pathol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/cncr.11127","article-title":"Bone markers in the management of patients with skeletal metastases","volume":"97","author":"Demers","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","article-title":"RANK ligand is a prerequesite for cancer-associated osteolytic lesions","volume":"198","author":"Kitazawa","year":"2002","journal-title":"J. Pathol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3346\/jkms.2003.18.4.541","article-title":"Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis","volume":"18","author":"Park","year":"2003","journal-title":"J. Korean Med. Sci"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0736-0266(02)00095-5","article-title":"Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone","volume":"21","author":"Lee","year":"2003","journal-title":"J. Orthop. Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/pros.1065","article-title":"Bone metastatic LNCaP-derived C4-2B prostate cancer cell line mineralises in vitro","volume":"47","author":"Lin","year":"2001","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0090-4295(00)01122-5","article-title":"Osteoprotegerin and RANK ligand expression in prostate cancer","volume":"57","author":"Brown","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB30","first-page":"1619","article-title":"Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells","volume":"62","author":"Holen","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB31","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/clinchem\/47.11.2061","article-title":"Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer","volume":"47","author":"Jung","year":"2001","journal-title":"Clin. Chem"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB32","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1097\/01.ju.0000094191.39574.cb","article-title":"Serum osteoprotegerin and receptor activator of nuclear factor-kappa B Ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer","volume":"170","author":"Jung","year":"2003","journal-title":"J. Urol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB33","first-page":"912","article-title":"Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells","volume":"63","author":"Shipman","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1359\/jbmr.2000.15.4.640","article-title":"Expression of osteoclast differentiation signals by stromal elements of giant cell tumors","volume":"15","author":"Atkins","year":"2000","journal-title":"J. Bone Miner. Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0002-9440(10)64942-5","article-title":"Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kB in giant cell tumor of bone","volume":"156","author":"Huang","year":"2000","journal-title":"Am. J. Pathol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/jor.1100180418","article-title":"Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells","volume":"18","author":"Miyamoto","year":"2000","journal-title":"J. Orthop. Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/mp.56.2.116","article-title":"Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment","volume":"56","author":"Huang","year":"2003","journal-title":"Mol. Pathol"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB38","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1172\/JCI13073","article-title":"Osteolysis and cancer","volume":"107","author":"Goltzman","year":"2001","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50","article-title":"Molecular mechanisms of tumor\u2013bone interactions in osteolytic metastases","volume":"10","author":"Chirgwin","year":"2000","journal-title":"Crit. Rev. Eukaryot. Gene Expr"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1006\/bbrc.1999.2008","article-title":"Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro","volume":"267","author":"Chikatsu","year":"2000","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0959-8049(00)00436-6","article-title":"Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines","volume":"37","author":"Perez","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB42","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/en.140.10.4451","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/jsre.2001.6204","article-title":"Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells","volume":"100","author":"Mancino","year":"2001","journal-title":"J. Surg. Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB44","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.bjc.6600858","article-title":"Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis","volume":"88","author":"Ohshiba","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB45","first-page":"2587","article-title":"Prostate cancer cells-osteoblast interaction shifts expression of growth\/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts","volume":"9","author":"Fizazi","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB46","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB47","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/bbrc.2000.2314","article-title":"Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF\/TRANCE that induces osteoclast formation","volume":"269","author":"Nagai","year":"2000","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB48","first-page":"1637","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma","volume":"61","author":"Michigami","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB49","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/01.blo.0000093055.96273.69","article-title":"Transforming growth factor-beta in osteolytic breast cancer bone metastases","volume":"415","author":"Guise","year":"2003","journal-title":"Clin. Orthop"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB50","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.3928\/0147-7447-20040102-17","article-title":"Measurement of bone morphogenetic proteins and other growth factors in demineralized bone matrix","volume":"27","author":"Blum","year":"2004","journal-title":"Orthopedics"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB51","first-page":"1686","article-title":"Un mod\u00e8le experimental d'ost\u00e9osarcome chez le rat: II. L'ost\u00e9osarcome greffable du rat","volume":"58","author":"Thi\u00e9ry","year":"1982","journal-title":"Sem. H\u00f4p. Paris"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB52","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S8756-3282(98)00141-0","article-title":"Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy","volume":"23","author":"Akatsu","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB54","first-page":"783","article-title":"Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy","volume":"60","author":"Capparelli","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/jor.1100180617","article-title":"Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice","volume":"18","author":"Clohisy","year":"2000","journal-title":"J. Orthop. Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB56","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.11125","article-title":"Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease","volume":"97","author":"Croucher","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB57","first-page":"287","article-title":"Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB58","first-page":"2096","article-title":"Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice","volume":"63","author":"Yonou","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB59","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/74999","article-title":"Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord","volume":"6","author":"Honore","year":"2000","journal-title":"Nat. Med"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB60","first-page":"4038","article-title":"Osteoprotegerin diminishes advanced bone cancer pain","volume":"61","author":"Luger","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB61","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S8756-3282(01)00404-5","article-title":"Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone","volume":"28","author":"Atkins","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB62","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB63","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB64","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB65","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.11134","article-title":"RANK-Fc: a therapeutic antagonist for RANKL in myeloma","volume":"97","author":"Sordillo","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB66","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.11133","article-title":"Receptor activator of NF-kB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma","volume":"97","author":"Oyajobi","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2004.05.002_BIB67","first-page":"274","article-title":"Disabling of RANK receptor complex by novel osteoprotegerin like peptidomimetics restores bone loss in-vivo","volume":"84","author":"Cheng","year":"2004","journal-title":"J. Biol. Chem"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X04000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X04000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T09:10:48Z","timestamp":1585818648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X04000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0304419X04000320"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2004.05.002","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}